The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled ...

Bioluminescent luciferase enzymes have historically been too dim to use as probes in living tissue. But recent advances have ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

Avidity Biosciences (RNA) announced the completion of enrollment in the biomarker cohort in the Phase 1/2 Fortitude clinical trial of ...

Flagship Pioneering-backed Sail Biomedicines has laid off 12 employees following a review of the company’s organizational ...